Need help calculating the Basic Earning Power (BEP) Ratio using this income statement info

Revenues	51750000
Cost of sales	10219000
Selling, informational & administrative expenses	14350000
Research & development expenses	8650000
Amortization of intangible assets	4610000
Restructuring charges & certain acquisition-related costs	747000
Gain (loss) on completion of Consumer Healthcare JV transaction	8086000
Interest income	226000
Interest expense	1574000
Net interest income (expense)	-1348000
Foreign currency gain (loss) related to Venezuela	-
Royalty-related income	648000
Net gains (losses) on asset disposals	31000
Net gains recognized during the period on equity securities	454000
Net realized gains (losses) on sales of investments in debt securities	-
Income from collaborations, out-licensing arrangements & sales of compound or product rights	168000
Net periodic benefit costs (credits) other than service costs	-64000
Certain legal matters, net	554000
Certain asset impairments	2843000
Business alignment costs	338000
Adjustments to loss on sale of HIS net assets	-
Loss on sale & impairment on remeasurement of HIS net assets	-
Business & legal entity alignment costs	-
Net losses (gains) on early retirement of debt	138000
GSK Consumer Healthcare JV equity method income (loss)	17000
Other income (deductions) - net	388000
Other income (deductions) - net	-3578000
Income (loss) from continuing operations before provision for taxes on income - U.S.	7931000
Income (loss) from continuing operations before provision for taxes on income - international	9751000
Income (loss) from continuing operations before provision (benefit) for taxes on income	17682000
Current federal income taxes provision (benefit)	-1641000
Current state & local income taxes provision (benefit)	-166000
Deferred federal income taxes provision (benefit)	1258000
Deferred state & local income taxes provision (benefit)	275000
Total U.S. tax provision (benefit)	-274000
TCJA - current income taxes provision (benefit)	-135000
TCJA - deferred Income taxes provision (benefit)	-187000
Total TCJA tax provision (benefit)	-323000
Current international income taxes provision (benefit)	2900000
Deferred international income taxes provision (benefit)	-919000
Total international tax provision (benefit)	1981000
Provision (benefit) for taxes on income	1384000
Income (loss) from continuing operations	16298000
Income (loss) from discontinued operations - net of tax	4000
Gain (loss) on disposal of discontinued operations - net of tax	-
Discontinued operations - net of tax	4000
Net income before allocation to noncontrolling interests	16302000
Less: net income attributable to noncontrolling interests	-29000
Net income attributable to Pfizer Inc.	16273000
Less: preferred stock dividends, net of tax	-
Net income attributable to Pfizer Inc. common shareholders	-
Weighted average shares outstanding - basic	5569000
Weighted average shares outstanding - diluted	5675000
Year end shares outstanding	5534000
Earnings (loss) per common share from continuing operations - basic	2.92
Net earnings (loss) per common share - basic	2.92
Earnings (loss) per common share from continuing operations - diluted	2.87
Net earnings (loss) per common share - diluted	2.87
Cash dividends paid per common share	-
Total number of employees	88300
Number of common stockholders	142524
Foreign currency translation adjustments	366000